Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase

NCT02708680 is registered in ClinicalTrials.gov with Syndax Pharmaceuticals as lead sponsor.

NCT NCT02708680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02708680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase
Lead sponsor
Syndax Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2016
Completion date
March 31, 2021
Enrollment
89 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer